9-nor-9β-Hydroxyhexahydrocannabinol

From Self-sufficiency
Revision as of 21:10, 21 September 2010 by Jontas (Talk | contribs) (1 revision)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
9-nor-9β-Hydroxyhexahydrocannabinol
200px
Systematic (IUPAC) name
6,6-dimethyl-3-pentyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromene-1,9-diol
Identifiers
CAS Number 52171-85-4
PubChem CID 6452587
Chemical data
Formula C20H30O3
Molar mass 318.449 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

9-nor-9β-Hydroxyhexahydrocannabinol (HHC), is a synthetic cannabinoid derivative which resulted from early modifications to the structure of THC, in a search for the simplest compound that could still fulfil the binding requirements to produce cannabis-like activity.[1][2] HHC is active in its own right with similar potency to THC, but further simplification and variation of this parent structure lead to more potent, yet structurally simpler derivatives such as CP 47,497 and CP 55,940,[3][4][5] which after several steps of modification have become quite structurally distinct from THC, while HHC on the other hand is still substantially similar in structure to THC.

The discovery of this simplified class of cannabinoid derivatives was highly significant in terms of the widespread use of CP 55,940 for early scientific research into the cannabinoid receptors,[6] as well as later work using more complex compounds such as CP 55,244 to map the CB1 binding site in more detail, but aside from these specific applications, these compounds attracted little attention and no compounds from this series were developed for medical use despite favourable safety profiles in animal studies. Unexpectedly some 25 years later, these compounds came back into prominence when an obscure derivative (C8)-CP 47,497 was found to have been sold as the active ingredient in the "herbal" cannabis substitute product Spice,[7] which ironically has led to a resurgence of interest into laboratory-conducted scientific research of this family of drugs.

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  1. Johnson MR, Althius TH, Bindra JS, Harbert CA, Melvin LS, Milne GM. Potent Analgetics Derived From 9-Nor-9β-Hydroxyhexahydrocannabinol. NIDA Research Monograph 34; 1980. pp 68-74.
  2. Melvin LS, Johnson MR. Structure-Activity Relationships of Tricyclic and Nonclassical Bicyclic Cannabinoids. NIDA Research Monograph 79; 1987. pp 31-47.
  3. Weissman A, Milne GM, Melvin LS Jr. Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol. Journal of Pharmacology and Experimental Therapeutics. 1982 Nov;223(2):516-23. PMID 6290642
  4. Melvin LS, Johnson MR, Harbert CA, Milne GM, Weissman A. A cannabinoid derived prototypical analgesic. Journal of Medicinal Chemistry. 1984 Jan;27(1):67-71. PMID 6690685
  5. Compton DR, Johnson MR, Melvin LS, Martin BR. Pharmacological profile of a series of bicyclic cannabinoid analogs: classification as cannabimimetic agents. Journal of Pharmacology and Experimental Therapeutics. 1992 Jan;260(1):201-9. PMID 1309872
  6. Devane WA, Dysarz FA 3rd, Johnson MR, Melvin LS, Howlett AC. Determination and characterization of a cannabinoid receptor in rat brain. Molecular Pharmacology. 1988 Nov;34(5):605-13. PMID 2848184
  7. Auwärter V, Dresen S, Weinmann W, Müller M, Pütz M, Ferreirós N. 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs? Journal of Mass Spectrometry. 2009 Feb 2. PMID 19189348